Меню
Идёт набор NCT05177523

Imaging the Interplay Between Axonal Damage and Repair in Multiple Sclerosis

Наблюдательное Multiple Sclerosis (MS) Relapsing-remitting Multiple Sclerosis (RRMS) Secondary-progressive Multiple Sclerosis (SPMS) Primary Progressive Multiple Sclerosis (PPMS)

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: MRI, Neurocognitive examination for healthy subjects, blood sampling.
Кому может быть актуально
Состояния в реестре: Multiple Sclerosis (MS), Relapsing-remitting Multiple Sclerosis (RRMS), Secondary-progressive Multiple Sclerosis (SPMS), Primary Progressive Multiple Sclerosis (PPMS). Базовые параметры: 18 лет — 80 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Швейцария
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Официальное название

INsIDER: Imaging the Interplay Between Axonal Damage and Repair in Multiple Sclerosis

Обзор

This project is to: 1. Quantify differences in axonal integrity and organization in aMS versus naPMS patients. 2. Quantify changes in axonal integrity and organization in aMS versus naPMS patients over a two-year period. 3. Validate the combination of imaging parameters that best differentiate aMS versus naPMS patients using histopathology.

Подробное описание

Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system characterized by multifocal inflammatory infiltrates, microglial activation and degradation of oligodendrocytes, myelin and axons. Clinical MS categories exhibit variable amount of central nervous system (CNS) damage and repair, depending on numerous variables including genetic, immunological, pathological and environmental factors.

Therefore, understanding the interplay between axonal damage (i.e. axonal demyelination/degeneration/loss/disorganization) and (ii) axonal repair (i.e. axonal remyelination/reorganization) in living MS patients may be the key to understand disease progression, to establish accurate disease monitoring criteria and to predict disease response to future reparative therapies. New in-vivo methods are necessary to elucidate the interplay between axonal damage and repair in the brain of living patients with MS. Advanced MRI (aMRI) permits a multifaced quantification of the various components of the axons and their organization. Neurite Orientation Dispersion and Density Imaging (NODDI) and Diffusion Kurtosis (DK) are new approaches in clinical research This study is to identify in vivo the specific neuropathological pattern of axonal damage and repair exhibited by active MS (aMS) and non-active progressive MS (naPMS) patient by leveraging the information provided by model-based diffusion metrics (NODDI, DK), Magnetization Transfer Imaging (MTI), Multi-echo Susceptibility-Based imaging (SBI), Myelin Water Imaging (MWI) and quantitative T1 relaxometry (qT1). These advanced MRI contrasts provide complementary and partially redundant information about the axonal structure and its organization (i.e. density and orientation of axons and dendrites in the brain tissue, axonal integrity and myelination, presence of myelin and iron, and brain tissue architecture). Therefore, their combination may prove high sensitivity and specificity to axonal damage and repair.

This project has 3 main aims:

Aim 1. Quantify differences in axonal integrity and organization in aMS versus naPMS patients.

Aim 2. Quantify changes in axonal integrity and organization in aMS versus naPMS patients over a two-year period.

Aim 3. Validate the combination of imaging parameters that best differentiate aMS versus naPMS patients using histopathology.

Вмешательства

  • Диагностический тест MRI
    Each enrolled subject will undergo a MRI at baseline and a second MRI at 2 years (+/- 3 months) follow-up.
  • Другое Neurocognitive examination for healthy subjects
    Neurocognitive examination for healthy subjects will be performed at both baseline and follow-up
  • Другое blood sampling
    Each enrolled subject will undergo a blood sampling (10 ml) at baseline

Первичные конечные точки

  • MRI- change in axonal integrity and organization over 2 years in aMS, naPMS and HC, by using machine learning techniques [Срок оценки: at baseline and 2 years (+/- 3 months) after baseline]
Вторичные конечные точки (5)
  • Change in MUSIC Test [Срок оценки: at baseline and 2 years (+/- 3 months) after baseline]
  • Change in auditory verbal learning and memory test/ Verbaler Lern- und Merkfähigkeitstest (VLMT) [Срок оценки: at baseline and 2 years (+/- 3 months) after baseline]
  • Change in Symbol Digital Modalities Test (SDMT) [Срок оценки: at baseline and 2 years (+/- 3 months) after baseline]
  • Change in Brief Visuospatial Memory Test (BVMT) [Срок оценки: at baseline and 2 years (+/- 3 months) after baseline]
  • Change in Hospital Anxiety and Depression Scale (HADS) [Срок оценки: at baseline and 2 years (+/- 3 months) after baseline]

Критерии участия

Inclusion Criteria for patients:

  • Patients may be diagnosed with:
  • active RRMS (n=100): Relapsing-remitting course and > 1 clinical relapse and/or signs of MRI activity (> 1 Gd enhancing lesion) during the last year before study enrollment.
  • non-active PMS (n=100): Progressive course (PPMS or SPMS) and no clinical relapses and/or signs of MRI activity during the last year before study enrollment.
  • Age 18-80 years old
  • No other neurological or psychiatric disorder

Inclusion criteria for healthy controls:

  • Age 18-80 years old
  • No other neurological or psychiatric disorder

Exclusion Criteria for patients and healthy controls:

  • Pregnancy
  • Contraindication to MRI (eg, claustrophobia, metallic implants, pacemaker etc).
  • Inability to give consent

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Да

Дизайн исследования

Модель наблюдения
Когортное

Центры проведения

Швейцария · 1 центр
  • University Hospital Basel, Department of Neurology — Basel

Идентификаторы

NCT: NCT05177523 · 2018-01174; me18Granziera

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗